Company Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection.
It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio.
The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019.
Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Country | United States |
Founded | 1996 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 20 |
CEO | Dr. Marc H. Hedrick M.B.A., M.D. |
Contact Details
Address: 4200 Marathon Blvd., Suite 200 Austin, Texas 78756 United States | |
Phone | 737.255.7194 |
Website | plustherapeutics.com |
Stock Details
Ticker Symbol | PSTV |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001095981 |
CUSIP Number | 72941H400 |
ISIN Number | US72941H5090 |
Employer ID | 33-0827593 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Dr. Marc H. Hedrick M.B.A., M.D. | President, Chief Executive Officer and Director |
Andrew J. Sims CPA | Vice President of Finance and Chief Financial Officer |
Dr. Norman D. LaFrance FACNP, FACP, M.D. | Chief Medical Officer and Senior Vice President |
Desiree Smith | Corporate Controller, Principal Financial and Accounting Officer |
Dr. John K. Fraser | Chief Scientist |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Jul 10, 2024 | ARS | Filing |
Jul 10, 2024 | DEF 14A | Other definitive proxy statements |
Jun 24, 2024 | EFFECT | Notice of Effectiveness |
Jun 24, 2024 | 424B3 | Prospectus |
Jun 24, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jun 7, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Jun 7, 2024 | 8-K | Current Report |
Jun 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jun 4, 2024 | 8-K | Current Report |